Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAT Open-Label Extension
NCT03657095Phase 3Terminated
- Sponsor
- Lung Biotechnology PBC
- Start
- Dec 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label trial of esuberaprost in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Lung Biotechnology PBC. Primary endpoint: Treatment Emergent Adverse Events at Month 7. Started Dec 2018; status: terminated.
02
Drugs
esuberaprost
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03657095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03657095.